Page last updated: 2024-09-05

erlotinib hydrochloride and Leukemia, Promyelocytic, Acute

erlotinib hydrochloride has been researched along with Leukemia, Promyelocytic, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Leukemia, Promyelocytic, Acute

Article	Year
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2013

Article

Year

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.

Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10

Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2013